Adaptive Biotechnologies (ADPT) Cash from Operations (2018 - 2026)

Adaptive Biotechnologies has disclosed Cash from Operations across 9 years of filings, most recently posting -$6.4 million for Q2 2026.

• In Q2 2026, Cash from Operations rose 48.51% year-over-year to -$6.4 million; the TTM figure through Jun 2026 stood at -$21.0 million (up 73.89% YoY), while the FY2025 annual figure was -$46.0 million, up 51.7% from the prior year.
• Cash from Operations came in at -$6.4 million for Q2 2026 at Adaptive Biotechnologies, up from -$9.5 million in the prior quarter.
• In the past five years, Cash from Operations ranged from a high of $2.1 million in Q4 2025 to a low of -$64.5 million in Q1 2022.
• Average Cash from Operations over 5 years is -$27.6 million, with a median of -$27.0 million recorded in 2023.
• Year-over-year, Cash from Operations declined 26.47% in 2022 and soared 116.45% in 2025.
• Over 5 years, Cash from Operations stood at -$30.0 million in 2022, then increased by 10.28% to -$26.9 million in 2023, then soared by 53.62% to -$12.5 million in 2024, then soared by 116.45% to $2.1 million in 2025, then plunged by 411.44% to -$6.4 million in 2026.
• Per Business Quant data, the three most recent Cash from Operations figures were -$6.4 million in Q2 2026, -$9.5 million in Q1 2026, and $2.1 million in Q4 2025.